[1]Li Y, Shi H, Wang WM,et al.Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study. Medicine (Baltimore). 2016 Jun;95(24):e3872.
[2]Eriksson D,Goldsmith D,Teitsson S,et al. Cross-sectional survey in?CKD?patients across Europe describing the association between quality of life and?anaemia. BMC Nephrol. 2016 Jul 26;17(1):97.
[3]Hayashi T,?Uemura Y,?Kumagai M, et al. Effect of achieved hemoglobin level on?renal?outcome?in non-dialysis?chronic kidney disease?(CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on?Renal?Survival in CKD patients with?renal?anemia?(MIRACLE-CKD Study). Clin Exp Nephrol. 2019 Mar;23(3):349-361.
[4]Portolés J, López-Gómez JM, Aljama P, MAR Study Group: A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol Dial Transplant. 2007; 22: 500–507.
[5]KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007 Sep;50(3):471-530.
[6]Priyadarshi A, Shapiro JI: Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial. 2006; 19: 273–278.
[7]KDOQI, National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47:S11–S145.
[8]Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(suppl 2):ii1–ii47.
[9]中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组：肾性贫血诊断与治疗中国专家共识（2018修订版）。中华肾脏病杂志，2018，34（11），860～866。
[10] Mehmet Kanbay，Mark A. Perazella，Benan Kasapoglu，et al. Erythropoiesis Stimulatory AgentResistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purif. 2010;29:1–12
[11]Tsuruya K,Uemura Y,Hirakata H,et al. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton).2017 Oct;22(10):769-775.
[12]Fukuma S，Yamaguchi T,Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis.2012 Jan;59(1):108-16.
[13]Luo J,Jensen DE,Maroni BJ, et al. Spectrum and Burden of Erythropoiesis- Stimulating Agent?Hyporesponsiveness?Among?Contemporary Hemodialysis?Patients. Am J Kidney Dis.2016 Nov;68(5):763-771.
[14]Koulouridis I, Alfayez M, Trikalinos TA,et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013 Jan;61(1):44-56.
[15]Okazaki M, Kaomatsu M, Kawaguchi H, et al. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif, 2014;37: 106–112.
[16]Sibbel SP, Koro CE, Brunelli SM,et al. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients. BMC Nephrol. 2015; 16:144.
[17]Rozen-Zvi B, Gafter-Gvili A, Paul M,et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008 Nov;52(5):897-906.
[18]Eriguchi R?,?Taniguchi M,?Ninomiya T, et al. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study. J Nephrol.?2015 Apr; 28(2):217-25.
[19]GillespieI A, MacdougallI C, Richards S,et al.Factors precipitating?erythropoiesis stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. Pharmacoepidemiol Drug Saf. 2015; 24(4):414-26.
[20]Ogawa T,?Nitta K. Erythropoiesis- stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol. 2015; 185: 76-86.
[21]Kartsios EC, Liakopoulos V, et al: Does hepcidin affect erythropoiesis in hemodialysispatients? Acta Haematol. 2006; 116: 238–244.
[22]Atanasiu V, Manolescu B, Stoian I: Hepcidin ：the link between inflammation and anemia in chronic renal failure, Rom. J Intern Med. 2006; 44: 25–33.
[23]Russo D, Morrone L, Di Iorio B, et al. Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease.J Nephrol. 2015;28:701-8.
[24]Lee CT,?Chou FF,?Chang HW, et al.?Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe?hyperparathyroidism. Blood Purif.?2003;21(6):369-75
[25]Yasunaga C,?Matsuo K,?Yanagida T,?et al. Early effects of parathyroidectomy on erythropoietin?production in secondary hyperparathyroidism. Am J Surg.2002 Feb;183(2):199-204
[26]Okazaki M,Komatsu M,Kawaguchi H, et al. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif.?2014;37(2):106-12
[27]Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int. 2011 Sep;80(5):464-74.
[28]Maisnar V, Chroust K: Treatment of associated anemia in different hematological disorders with epoetin alpha. Neoplasma. 2004; 51: 379–384.
[29]Bohlius J, Bohlke K, Castelli R, et al.Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019 Apr 23;3(8):1197-1210.
[30]Macdougall IC. Antibody -mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv9-15.
[31]Praditpornsilpa K, Tiranathanagul K, Kupatawintu P,et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011 Jul;80(1):88-92.
[32]Johnson DW,?Pascoe EM,?Badve SV，et al. A randomized, placebo-controlled trial of pentoxifylline on?erythropoiesis- stimulating agent?hyporesponsiveness?in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Am J Kidney Dis.?2015 Jan;65(1):49-57.
[33]Mohammadpour AH, Nazemian F, Khaiat MH,et al. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients.Saudi J Kidney Dis Transpl. 2014 Jan;25(1):73-8.
[34]Sui Z?,?Wang M,?Zuo L. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China.Medicine (Baltimore).?2019 Jan;98(2):e13981.
[35]Hasegawa T?,?Zhao J,?Fuller DS,et al. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins. Am J Nephrol.?2017;46(1):11-17.
[36]Hurot JM, Cucherat M, Haugh M,et al.Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002 Mar;13(3):708-14.
[37]Chen N, Hao C, Liu BC,et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.N Engl J Med. 2019 Sep 12;381(11):1011-1022.
[38]Chen N, Hao C, Peng X, et al.Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med. 2019 Sep 12;381(11):1001-1010.
[39]Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) Versus Epoetin Alfa for?Anemia?in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Am J Kidney Dis.?2016 Jun;67(6):912-24.
[40]Jansz TT,??zyilmaz A,?Grooteman MPC,et al. Long-term clinical parameters after switching to nocturnal haemodialysis: a Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration. BMJ Open.?2018 Mar 8;8(3):e019900.
[41]Marcelli D,?Bayh I,?Merello JI, et al. Dynamics of the?erythropoiesis stimulating?agent?resistance index in incident hemodiafiltration and high-flux hemodialysis patients. Kidney Int.?2016 Jul;90(1):192-202.
[42]Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis. Nephrol Dial Transplant. 2013 Feb;28(2):438-46.
